Kane Biotech (TSXV:KNE) Long-Term Debt : C$1.05 Mil (As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Kane Biotech Long-Term Debt?

Kane Biotech's Long-Term Debt for the quarter that ended in Sep. 2024 was C$1.05 Mil.

Kane Biotech's quarterly Long-Term Debt declined from Mar. 2024 (C$1.22 Mil) to Jun. 2024 (C$1.14 Mil) and declined from Jun. 2024 (C$1.14 Mil) to Sep. 2024 (C$1.05 Mil).

Kane Biotech's annual Long-Term Debt increased from Dec. 2021 (C$1.12 Mil) to Dec. 2022 (C$1.60 Mil) but then declined from Dec. 2022 (C$1.60 Mil) to Dec. 2023 (C$1.30 Mil).

Kane Biotech Long-Term Debt Historical Data

The historical data trend for Kane Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kane Biotech Long-Term Debt Chart

Kane Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

0.15

0.66

1.12

1.60

1.30

Kane Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															1.39	1.30	1.22	1.14	1.05

Kane Biotech (TSXV:KNE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Kane Biotech Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Kane Biotech's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kane Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (TSXV:KNE) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

KNBIF:USA

Address

290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2

Website

https://www.kanebiotech.com

Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.

Executives

Marc Edwards	Director
Philip Renaud	Director
Raymond David Eugene Dupuis	Senior Officer
Richard J. Renaud	10% Security Holder
Georges Morin	Director
Rashieda Gluck	Director

Kane Biotech Headlines

No Headlines